RUNX1 and RUNX1-ETO: Roles in hematopoiesis and leukemogenesis

Frontiers in Bioscience

Volumn 17, Issue 3, 2012, Pages 1120-1139

  Lam, Kentson ^a   Zhang, Dong Er ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AML; AML1; AML1 ETO; CBFA2; Hematopoiesis; Hematopoietic stem cells; Leukemia; Leukemogenesis; Mouse models; Review; RUNX1; RUNX1 ETO; RUNX1 RUNX1T1

Indexed keywords

ANIMALIA;

ONCOPROTEIN; RUNX1 PROTEIN, HUMAN; RUNX1T1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1;

CHEMISTRY; GENE TRANSLOCATION; GENETICS; HEMATOPOIESIS; HUMAN; LEUKEMIA; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW;

CORE BINDING FACTOR ALPHA 2 SUBUNIT; HEMATOPOIESIS; HUMANS; LEUKEMIA; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84859243940     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3977     Document Type: Article

References (181)

1. van Wijnen, A J, G. S. Stein, J. P. Gergen, Y. Groner, S. W. Hiebert, Y. Ito, P. Liu, J. C. Neil, M. Ohki, & N. Speck: Nomenclature for Runt-related (RUNX) proteins. Oncogene 23, 4209-4210 (2004). (Pubitemid 38758585)
2. Nussleinvolhard, C & E. Wieschaus: Mutations Affecting Segment Number and Polarity in Drosophila. Nature 287, 795-801 (1980). (Pubitemid 11214475)
3. Kania, M A, A. S. Bonner, J. B. Duffy, & J. P. Gergen: The Drosophila Segmentation Gene Runt Encodes A Novel Nuclear Regulatory Protein That Is Also Expressed in the Developing Nervous-System. Genes & Development 4, 1701-1713 (1990).
4. Kagoshima, H, K. Shigesada, M. Satake, Y. Ito, H. Miyoshi, M. Ohki, M. Pepling, & P. Gergen: The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet 9, 338-341 (1993). (Pubitemid 23296286)
5. Speck, N A & D. Baltimore: 6 Distinct Nuclear Factors Interact with the 75-Base-Pair Repeat of the Moloney Murine Leukemia-Virus Enhancer. Molecular and Cellular Biology 7, 1101-1110 (1987). (Pubitemid 17017431)
6. Satake, M, T. Ibaraki, & Y. Ito: Modulation of Polyomavirus Enhancer Binding-Proteins by Ha-Ras Oncogene. Oncogene 3, 69-78 (1988).
7. Kamachi, Y, E. Ogawa, M. Asano, S. Ishida, Y. Murakami, M. Satake, Y. Ito, & K. Shigesada: Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J Virol 64, 4808-4819 (1990). (Pubitemid 20329800)
8. Miyoshi, H, K. Shimizu, T. Kozu, N. Maseki, Y. Kaneko, & M. Ohki: t(8, 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88, 10431-10434 (1991). (Pubitemid 21915849)
9. Rowley, J D: Identification of A Translocation with Quinacrine Fluorescence in A Patient with Acute Leukemia. Annales de Genetique 16, 109-112 (1973).
10. Rowley, J D: The clinical usefulness of chromosome studies in patients with leukemia. Compr Ther 6, 57-64 (1980). (Pubitemid 11235525)
11. Peterson, L F & D. E. Zhang: The 8, 21 translocation in leukemogenesis. Oncogene 23, 4255-4262 (2004).
12. Rhoades, K L, C. J. Hetherington, N. Harakawa, D. A. Yergeau, L. Zhou, L. Q. Liu, M. T. Little, D. G. Tenen, & D. E. Zhang: Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96, 2108-2115 (2000).
13. Yuan, Y, L. Zhou, T. Miyamoto, H. Iwasaki, N. Harakawa, C. J. Hetherington, S. A. Burel, E. Lagasse, I. L. Weissman, K. Akashi, & D. E. Zhang: AML1-ETO expression is directly involved in the development of acutemyeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98, 10398-10403 (2001). (Pubitemid 32803031)
14. Levanon, D, G. Glusman, T. Bangsow, E. Ben-Asher, D. A. Male, N. Avidan, C. Bangsow, M. Hattori, T. D. Taylor, S. Taudien, K. Blechschmidt, N. Shimizu, A. Rosenthal, Y. Sakaki, D. Lancet, & Y. Groner: Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene 262, 23-33 (2001). (Pubitemid 32155331)
15. Miyoshi, H, M. Ohira, K. Shimizu, K. Mitani, H. Hirai, T. Imai, K. Yokoyama, E. Soeda, & M. Ohki: Alternative Splicing and Genomic Structure of the Aml1 Gene Involved in Acute Myeloid-Leukemia. Nucleic Acids Research 23, 2762-2769 (1995).
16. Tanaka, T, K. Tanaka, S. Ogawa, M. Kurokawa, K. Mitani, J. Nishida, Y. Shibata, Y. Yazaki, & H. Hirai: An Acute Myeloid-Leukemia Gene, Aml1, Regulates Hematopoietic Myeloid Cell-Differentiation and Transcriptional Activation Antagonistically by 2 Alternative Spliced Forms. Embo Journal 14, 341-350 (1995).
17. Tsuzuki, S, D. L. Hong, R. Gupta, K. Matsuo, M. Seto, & T. Enver: Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Medicine 4, 880-896 (2007).
18. Liu, X, Q. Zhang, D. E. Zhang, C. Zhou, H. Xing, Z. Tian, Q. Rao, M. Wang, & J. Wang: Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia 23, 739-745 (2009).
19. Telfer, J C & E. V. Rothenberg: Expression and function of a stem cell promoter for the murine CBF alpha 2 gene: Distinct roles and regulation in natural killer and T cell development. Developmental Biology 229, 363-382 (2001). (Pubitemid 32108698)
20. Lam, E Y, J. Y. Chau, M. L. Kalev-Zylinska, T. M. Fountaine, R. S. Mead, C. J. Hall, P. S. Crosier, K. E. Crosier, & M. V. Flores: Zebrafish runx1 promoter-EGFP transgenics mark discrete sites of definitive blood progenitors. Blood 113, 1241-1249 (2009).
21. Sroczynska, P, C. Lancrin, V. Kouskoff, & G. Lacaud: The differential activities of Runx1 promoters define milestones during embryonic hematopoiesis. Blood 114, 5279-5289 (2009).
22. Pozner, A, J. Lotem, C. Xiao, D. Goldenberg, O. Brenner, V. Negreanu, D. Levanon, & Y. Groner: Developmentally regulated promoter-switch transcriptionally controls Runx I function during embryonic hematopoiesis. BMC Developmental Biology 7, (2007).
23. Bee, T, G. Swiers, S. Muroi, A. Pozner, W. Nottingham, A. C. Santos, P. S. Li, I. Taniuchi, & M. F. T. R. de Bruijn: Nonredundant roles for Runx1 alternative promoters reflect their activity at discrete stages of developmental hematopoiesis. Blood 115, 3042-3050 (2010).
24. Nottingham, W T, A. Jarratt, M. Burgess, C. L. Speck, J. F. Cheng, S. Prabhakar, E. M. Rubin, P. S. Li, J. Sloane-Stanley, A. S. Kong, & M. F. T. R. de Bruijn: Runx1- mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer. Blood 110, 4188- 4197 (2007). (Pubitemid 351377782)
25. Ng, C E L, T. Yokomizo, N. Yamashita, B. Cirovic, H. Jin, Z. L. Wen, Y. Ito, & M. Osato: A Runx1 Intronic Enhancer Marks Hemogenic Endothelial Cells and Hematopoietic Stem Cells. Stem Cells 28, 1869-1881 (2010).
26. Bee, T, E. L. K. Ashley, S. R. B. Bickley, A. Jarratt, P. S. Li, J. Sloane-Stanley, B. Gottgens, & M. F. T. R. de Bruijn: The mouse Runx1+23 hematopoietic stem cell enhancer confers hematopoietic specificity to both Runx1 promoters. Blood 113, 5121-5124 (2009).
27. Ogawa, E, M. Maruyama, H. Kagoshima, M. Inuzuka, J. Lu, M. Satake, K. Shigesada, & Y. Ito: PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci USA 90, 6859-6863 (1993). (Pubitemid 23207313)
28. Wang, S, Q. Wang, B. E. Crute, I. N. Melnikova, S. R. Keller, & N. A. Speck: Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 13, 3324-3339 (1993). (Pubitemid 23157270)
29. Berardi, M J, C. H. Sun, M. Zehr, F. Abildgaard, J. Peng, N. A. Speck, & J. H. Bushweller: The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure 7, 1247-1256 (1999). (Pubitemid 29482986)
30. Nagata, T, V. Gupta, D. Sorce, W. Y. Kim, A. Sali, B. T. Chait, K. Shigesada, Y. Ito, & M. H. Werner: Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nature Structural Biology 6, 615-619 (1999). (Pubitemid 29318947)
31. Warren, A J, J. Bravo, R. L. Williams, & T. H. Rabbitts: Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta. EMBO J 19, 3004-3015 (2000). (Pubitemid 30386771)
32. Tahirov, T H, T. Inoue-Bungo, H. Morii, A. Fujikawa, M. Sasaki, K. Kimura, M. Shiina, K. Sato, T. Kumasaka, M. Yamamoto, S. Ishii, & K. Ogata: Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 104, 755-767 (2001). (Pubitemid 32241025)
33. Bartfeld, D, L. Shimon, G. C. Couture, D. Rabinovich, F. Frolow, D. Levanon, Y. Groner, & Z. Shakked: DNA recognition by the RUNX1 transcription factor is mediatedby an allosteric transition in the Runt domain and by DNA bending. Structure 10, 1395-1407 (2002). (Pubitemid 35232385)
34. Kanno, T, Y. Kanno, L. F. Chen, E. Ogawa, W. Y. Kim, & Y. Ito: Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol 18, 2444-2454 (1998). (Pubitemid 28183414)
35. Gu, T L, T. L. Goetz, B. J. Graves, & N. A. Speck: Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol 20, 91-103 (2000). (Pubitemid 30002551)
36. Zeng, C, S. McNeil, S. Pockwinse, J. Nickerson, L. Shopland, J. B. Lawrence, S. Penman, S. Hiebert, J. B. Lian, A. J. van Wijnen, J. L. Stein, & G. S. Stein: Intranuclear targeting of AML/CBFalpha regulatory factors to nuclear matrix-associated transcriptional domains. Proc Natl Acad Sci USA 95, 1585-1589 (1998). (Pubitemid 28103436)
37. Aronson, B D, A. L. Fisher, K. Blechman, M. Caudy, & J. P. Gergen: Groucho-dependent and -independent repression activities of Runt domain proteins. Mol Cell Biol 17, 5581-5587 (1997). (Pubitemid 27357654)
38. Levanon, D, R. E. Goldstein, Y. Bernstein, H. Tang, D. Goldenberg, S. Stifani, Z. Paroush, & Y. Groner: Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci USA 95, 11590-11595 (1998). (Pubitemid 28460459)
39. Telfer, J C, E. E. Hedblom, M. K. Anderson, M. N. Laurent, & E. V. Rothenberg: Localization of the domains in Runx transcription factors required for the repression of CD4 in thymocytes. J Immunol 172, 4359-4370 (2004). (Pubitemid 38375251)
40. Gunther, C V & B. J. Graves: Identification of ETS domain proteins in murine T lymphocytes that interact with the Moloney murine leukemia virus enhancer. Mol Cell Biol 14, 7569-7580 (1994). (Pubitemid 24326423)
41. Kim, W Y, M. Sieweke, E. Ogawa, H. J. Wee, U. Englmeier, T. Graf, & Y. Ito: Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 18, 1609-1620 (1999). (Pubitemid 29127073)
42. Zhang, D E, C. J. Hetherington, S. Meyers, K. L. Rhoades, C. J. Larson, H. M. Chen, S. W. Hiebert, & D. G. Tenen: CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 16, 1231-1240 (1996). (Pubitemid 26061693)
43. Petrovick, M S, S. W. Hiebert, A. D. Friedman, C. J. Hetherington, D. G. Tenen, & D. E. Zhang: Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol 18, 3915-3925 (1998). (Pubitemid 28287915)
44. Kitabayashi, I, A. Yokoyama, K. Shimizu, & M. Ohki: Interaction and functional cooperation of the leukemiaassociated factors AML1 and p300 in myeloid cell differentiation. EMBO J 17, 2994-3004 (1998). (Pubitemid 28254372)
45. Imai, Y, M. Kurokawa, Y. Yamaguchi, K. Izutsu, E. Nitta, K. Mitani, M. Satake, T. Noda, Y. Ito, & H. Hirai: The corepressor mSin3A regulates phosphorylationinduced activation, intranuclear location, and stability of AML1. Mol Cell Biol 24, 1033-1043 (2004). (Pubitemid 38112168)
46. Xu, G, R. Kanezaki, T. Toki, S. Watanabe, Y. Takahashi, K. Terui, I. Kitabayashi, & E. Ito: Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia 20, 1002-1008 (2006). (Pubitemid 43797291)
47. Huang, H, M. Yu, T. E. Akie, T. B. Moran, A. J. Woo, N. Tu, Z. Waldon, Y. Y. Lin, H. Steen, & A. B. Cantor: Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol 29, 4103-4115 (2009).
48. Tanaka, T, M. Kurokawa, K. Ueki, K. Tanaka, Y. Imai, K. Mitani, K. Okazaki, N. Sagata, Y. Yazaki, Y. Shibata, T. Kadowaki, & H. Hirai: The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 16, 3967-3979 (1996). (Pubitemid 26199916)
49. Erickson, P F, G. Dessev, R. S. Lasher, G. Philips, M. Robinson, & H. A. Drabkin: ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8, 21) leukemogenesis and monitoring residual disease. Blood 88, 1813-1823 (1996). (Pubitemid 26307079)
50. Zhang, Y, J. R. Biggs, & A. S. Kraft: Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 279, 53116-53125 (2004). (Pubitemid 40051813)
51. Biggs, J R, L. F. Peterson, Y. Zhang, A. S. Kraft, & D. E. Zhang: AML1/RUNX1 phosphorylation by cyclindependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol 26, 7420-7429 (2006). (Pubitemid 44547694)
52. Zhang, L, F. B. Fried, H. Guo, & A. D. Friedman: Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111, 1193-1200 (2008). (Pubitemid 351213400)
53. Aikawa, Y, L. A. Nguyen, K. Isono, N. Takakura, Y. Tagata, M. L. Schmitz, H. Koseki, & I. Kitabayashi: Roles of HIPK1 and HIPK2 in in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 25, 3955-3965 (2006). (Pubitemid 44338738)
54. Wee, H J, D. C. C. Voon, S. C. Bae, & Y. Ito: PEBP2- beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112, 3777-3787 (2008).
55. Guo, H & A. D. Friedman: Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J Biol Chem 286, 208-215 (2011).
56. Muratani, M & W. P. Tansey: How the ubiquitinproteasome system controls transcription. Nat Rev Mol Cell Biol 4, 192-201 (2003). (Pubitemid 36288041)
57. Huang, G, K. Shigesada, K. Ito, H. J. Wee, T. Yokomizo, & Y. Ito: Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin- proteasomemediated degradation. EMBO J 20, 723-733 (2001). (Pubitemid 32167637)
58. Zhao, X, V. Jankovic, A. Gural, G. Huang, A. Pardanani, S. Menendez, J. Zhang, R. Dunne, A. Xiao, H. Erdjument-Bromage, C. D. Allis, P. Tempst, & S. D. Nimer: Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev 22, 640-653 (2008). (Pubitemid 351342436)
59. Tachibana, M, C. Tezuka, S. Muroi, S. Nishimoto, T. Katsumoto, A. Nakajima, I. Kitabayashi, & I. Taniuchi: Phosphorylation of Runx1 at Ser249, Ser266, and Ser276 is dispensable for bone marrow hematopoiesis and thymocyte differentiation. Biochem Biophys Res Commun 368, 536- 542 (2008).
60. Palis, J, S. Robertson, M. Kennedy, C. Wall, & G. Keller: Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. Development 126, 5073-5084 (1999). (Pubitemid 30000420)
61. Medvinsky, A L, N. L. Samoylina, A. M. Muller, & E. A. Dzierzak: An Early Pre-Liver Intra-Embryonic Source of Cfu-S in the Developing Mouse. Nature 364, 64-67 (1993). (Pubitemid 23233456)
62. Medvinsky, A & E. Dzierzak: Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86, 897- 906 (1996). (Pubitemid 26336794)
63. North, T, T. L. Gu, T. Stacy, Q. Wang, L. Howard, M. Binder, M. Marin-Padilla, & N. A. Speck: Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 126, 2563-2575 (1999). (Pubitemid 29299024)
64. Okuda, T, van Deursen J., S. W. Hiebert, G. Grosveld, & J. R. Downing: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321- 330 (1996). (Pubitemid 26042836)
65. Wang, Q, T. Stacy, J. D. Miller, A. F. Lewis, T. L. Gu, X. Huang, J. H. Bushweller, J. C. Bories, F. W. Alt, G. Ryan, P. P. Liu, A. Wynshaw-Boris, M. Binder, M. Marin- Padilla, A. H. Sharpe, & N. A. Speck: The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87, 697-708 (1996). (Pubitemid 26386943)
66. Takakura, N, T. Watanabe, S. Suenobu, Y. Yamada, T. Noda, Y. Ito, M. Satake, & T. Suda: A role for hematopoietic stem cells in promoting angiogenesis. Cell 102, 199-209 (2000).
67. Lancrin, C, P. Sroczynska, C. Stephenson, T. Allen, V. Kouskoff, & G. Lacaud: The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 457, 892-895 (2009).
68. Chen, M J, T. Yokomizo, B. M. Zeigler, E. Dzierzak, & N. A. Speck: Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457, 887-891 (2009).
69. Sun, W & J. R. Downing: Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood 104, 3565-3572 (2004). (Pubitemid 39564428)
70. Ichikawa, M, T. Asai, T. Saito, S. Seo, I. Yamazaki, T. Yamagata, K. Mitani, S. Chiba, S. Ogawa, M. Kurokawa, & H. Hirai: AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10, 299-304 (2004). (Pubitemid 38667622)
71. Growney, J D, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, N. A. Speck, & D. G. Gilliland: Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 494-504 (2005). (Pubitemid 40981243)
72. Putz, G, A. Rosner, I. Nuesslein, N. Schmitz, & F. Buchholz: AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25, 929-939 (2006). (Pubitemid 43237711)
73. Kuhn, R, F. Schwenk, M. Aguet, & K. Rajewsky: Inducible gene targeting in mice. Science 269, 1427-1429 (1995).
74. Ichikawa, M, S. Goyama, T. Asai, M. Kawazu, M. Nakagawa, M. Takeshita, S. Chiba, S. Ogawa, & M. Kurokawa: AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. Journal of Immunology 180, 4402-4408 (2008).
75. Jacob, B, M. Osato, N. Yamashita, C. Q. Wang, I. Taniuchi, D. R. Littman, N. Asou, & Y. Ito: Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood 115, 1610-1620 (2010).
76. Hoogenkamp, M, M. Lichtinger, H. Krysinska, C. Lancrin, D. Clarke, A. Williamson, L. Mazzarella, R. Ingram, H. Jorgensen, A. Fisher, D. G. Tenen, V. Kouskoff, G. Lacaud, & C. Bonifer: Early chromatin unfolding by RUNX1: a molecular explanation for differential requirements during specification versus maintenance of the hematopoietic gene expression program. Blood 114, 299-309 (2009).
77. Meyers, S, J. R. Downing, & S. W. Hiebert: Identification of AML-1 and the (8, 21) translocation protein (AML- 1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNAbinding and protein-protein interactions. Mol Cell Biol 13, 6336-6345 (1993). (Pubitemid 23292627)
78. Cameron, S, D. S. Taylor, E. C. TePas, N. A. Speck, & B. Mathey-Prevot: Identification of a critical regulatory site in the human interleukin- 3 promoter by in vivo footprinting. Blood 83, 2851-2859 (1994). (Pubitemid 24142716)
79. Takahashi, A, M. Satake, Y. Yamaguchi-Iwai, S. C. Bae, J. Lu, M. Maruyama, Y. W. Zhang, H. Oka, N. Arai, & K. Arai: Positive and negative regulation of granulocytemacrophage colony- stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 86, 607- 616 (1995).
80. Zhang, D E, K. Fujioka, C. J. Hetherington, L. H. Shapiro, H. M. Chen, A. T. Look, & D. G. Tenen: Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 14, 8085-8095 (1994). (Pubitemid 24373557)
81. Satoh, Y, I. Matsumura, H. Tanaka, S. Ezoe, K. Fukushima, M. Tokunaga, M. Yasumi, H. Shibayama, M. Mizuki, T. Era, T. Okuda, & Y. Kanakura: AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells. Journal of Biological Chemistry 283, 30045- 30056 (2008).
82. Nuchprayoon, I, S. Meyers, L. M. Scott, J. Suzow, S. Hiebert, & A. D. Friedman: PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 14, 5558-5568 (1994). (Pubitemid 24235984)
83. Ogihara, H, T. Kanno, E. Morii, D. K. Kim, Y. M. Lee, M. Sato, W. Y. Kim, S. Nomura, Y. Ito, & Y. Kitamura: Synergy of PEBP2/CBF with mi transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene. Oncogene 18, 4632-4639 (1999). (Pubitemid 29405895)
84. Hsiang, Y H, D. Spencer, S. Wang, N. A. Speck, & D. H. Raulet: The role of viral enhancer "core" motif-related sequences in regulating T cell receptor-gamma and -delta gene expression. J Immunol 150, 3905-3916 (1993). (Pubitemid 23129772)
85. Sun, W, B. J. Graves, & N. A. Speck: Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J Virol 69, 4941-4949 (1995).
86. Puig-Kroger, A, C. Lopez-Rodriguez, M. Relloso, T. Sanchez-Elsner, A. Nueda, E. Munoz, C. Bernabeu, & A. L. Corbi: Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter. J Biol Chem 275, 28507-28512 (2000).
87. Libermann, T A, Z. Pan, Y. Akbarali, C. J. Hetherington, J. Boltax, D. A. Yergeau, & D. E. Zhang: AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cellspecific BLK gene promoter. J Biol Chem 274, 24671- 24676 (1999).
88. Zhang, Y & R. Derynck: Transcriptional regulation of the transforming growth factor-beta - inducible mouse germ line Ig alpha constant region gene by functional cooperation of Smad, CREB, and AML family members. J Biol Chem 275, 16979-16985 (2000). (Pubitemid 30398938)
89. Erman, B, M. Cortes, B. S. Nikolajczyk, N. A. Speck, & R. Sen: ETS-core binding factor: a common composite motif in antigen receptor gene enhancers. Mol Cell Biol 18, 1322-1330 (1998). (Pubitemid 28100896)
90. Kitoh, A, M. Ono, Y. Naoe, N. Ohkura, T. Yamaguchi, H. Yaguchi, I. Kitabayashi, T. Tsukada, T. Nomura, Y. Miyachi, I. Taniuchi, & S. Sakaguchi: Indispensable Role of the Runx1-Cbf beta Transcription Complex for In vivo- Suppressive Function of FoxP3(+) Regulatory T Cells. Immunity 31, 609-620 (2009).
91. Rudra, D, T. Egawa, M. M. W. Chong, P. Treuting, D. R. Littman, & A. Y. Rudensky: Runx-CBF beta complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nature Immunology 10, 1170-1U53 (2009).
92. Huang, G, P. Zhang, H. Hirai, S. Elf, X. Yan, Z. Chen, S. Koschmieder, Y. Okuno, T. Dayaram, J. D. Growney, R. A. Shivdasani, D. G. Gilliland, N. A. Speck, S. D. Nimer, & D. G. Tenen: PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nature Genetics 40, 51-60 (2008).
93. Ben Ami, O, N. Pencovich, J. Lotem, D. Levanon, & Y. Groner: A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proc Natl Acad Sci USA 106, 238-243 (2009).
94. Osato M., Asou N., Abdalla E., Hoshino K., Yamasaki H., Okubo T., Suzushima H., Takatsuki K., Kanno T., Shigesada K., & Ito Y.: Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2aB gene associated with myeloblastic leukemias. Blood 93, 1817- 1824 (1999). (Pubitemid 29128481)
95. Song, W J, M. G. Sullivan, R. D. Legare, S. Hutchings, X. Tan, D. Kufrin, J. Ratajczak, I. C. Resende, C. Haworth, R. Hock, M. Loh, C. Felix, D. C. Roy, L. Busque, D. Kurnit, C. Willman, A. M. Gewirtz, N. A. Speck, J. H. Bushweller, F. P. Li, K. Gardiner, M. Poncz, J. M. Maris, & D. G. Gilliland: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23, 166-175 (1999). (Pubitemid 29455388)
96. Preudhomme, C, A. Renneville, V. Bourdon, N. Philippe, C. Roche-Lestienne, N. Boissel, N. Dhedin, J. M. Andre, P. Cornillet-Lefebvre, A. Baruchel, M. J. Mozziconacci, & H. Sobol: High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113, 5583-5587 (2009).
97. Imai, Y, M. Kurokawa, K. Izutsu, A. Hangaishi, K. Takeuchi, K. Maki, S. Ogawa, S. Chiba, K. Mitani, & H. Hirai: Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96, 3154-3160 (2000).
98. Michaud, J, F. Wu, M. Osato, G. M. Cotties, M. Yanagida, N. Asou, K. Shigesada, Y. Ito, K. F. Benson, W. H. Raskind, C. Rossier, S. E. Antonarakis, S. Israels, A. McNicol, H. Weiss, M. Horwitz, & H. S. Scott: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 99, 1364-1372 (2002). (Pubitemid 34547093)
99. Heller, P G, A. C. Glembotsky, M. J. Gandhi, C. L. Cummings, C. J. Pirola, R. F. Marta, L. I. Kornblihtt, J. G. Drachman, & F. C. Molinas: Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood 105, 4664-4670 (2005). (Pubitemid 40807286)
100. Churpek, J E, J. S. Garcia, J. Madzo, S. A. Jackson, K. Onel, & L. A. Godley: Identification and molecular characterization of a novel 3 ' mutation in RUNX1 in a family with familial platelet disorder. Leukemia & Lymphoma 51, 1931-1935 (2010).
101. Ding, Y, Y. Harada, J. Imagawa, A. Kimura, & H. Harada: AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 114, 5201-5205 (2009).
102. Wang, W, S. Schwemmers, E. O. Hexner, & H. L. Pahl: AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617Findependent overexpression of NF-E2. Blood 116, 254-266 (2010).
103. Gelsi-Boyer, V, V. Trouplin, J. Adelaide, N. Aceto, V. Remy, S. Pinson, C. Houdayer, C. Arnoulet, D. Sainty, M. Bentires-Alj, S. Olschawang, N. Vey, M. J. Mozziconacci, D. Birnbaum, & M. Chaffanet: Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 8, (2008).
104. Kuo, M C, D. C. Liang, C. F. Huang, Y. S. Shih, J. H. Wu, T. L. Lin, & L. Y. Shih: RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 23, 1426-1431 (2009).
105. Look, A T: Oncogenic transcription factors in the human acute leukemias. Science 278, 1059-1064 (1997). (Pubitemid 27517875)
106. Golub, T R, G. F. Barker, S. K. Bohlander, S. W. Hiebert, D. C. Ward, P. Bray-Ward, E. Morgan, S. C. Raimondi, J. D. Rowley, & D. G. Gilliland: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92, 4917-4921 (1995).
107. Zelent, A, M. Greaves, & T. Enver: Role of the TELAML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23, 4275-4283 (2004). (Pubitemid 38765136)
108. Rubin, C M, R. A. Larson, M. A. Bitter, J. J. Carrino, M. M. LeBeau, M. O. Diaz, & J. D. Rowley: Association of A Chromosomal 3-21 Translocation with the Blast Phase of Chronic Myelogenous Leukemia. Blood 70, 1338-1342 (1987). (Pubitemid 18026135)
109. Rubin, C M, R. A. Larson, J. Anastasi, J. N. Winter, M. Thangavelu, J. W. Vardiman, J. D. Rowley, & M. M. LeBeau: T(3-21)(Q26-Q22) - A Recurring Chromosomal Abnormality in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid-Leukemia. Blood 76, 2594- 2598 (1990).
110. Nucifora, G, C. R. Begy, H. Kobayashi, D. Roulston, D. Claxton, J. Pedersenbjergaard, E. Parganas, J. N. Ihle, & J. D. Rowley: Consistent Intergenic Splicing and Production of Multiple Transcripts Between Aml1 at 21Q22 and Unrelated Genes at 3Q26 in (321)(Q26Q22) Translocations. Proceedings of the National Academy of Sciences of the United States of America 91, 4004-4008 (1994). (Pubitemid 24139561)
111. Mikhail, F M, K. A. Serry, N. Hatem, Z. I. Mourad, H. M. Farawela, D. M. El Kaffash, L. Coignet, & G. Nucifora: A new translocation that rearranges the AML1 gene in a patient with T-cell acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics 135, 96-100 (2002). (Pubitemid 34601179)
112. Gamou, T, E. Kitamura, F. Hosoda, K. Shimizu, K. Shinohara, Y. Hayashi, T. Nagase, Y. Yokoyama, & M. Ohki: The partner gene of AML1 in t(16, 21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91, 4028-4037 (1998). (Pubitemid 28261962)
113. Chan, E M, E. M. Comer, F. C. Brown, K. E. Richkind, M. L. Holmes, B. H. Chong, R. Shiffman, D. E. Zhang, M. L. Slovak, C. L. Willman, C. T. Noguchi, Y. J. Li, D. J. Heiber, L. Kwan, R. J. Chan, G. H. Vance, H. C. Ramsey, & R. A. Hromas: AML1-FOG2 fusion protein in myelodysplasia. Blood 105, 4523-4526 (2005). (Pubitemid 40720803)
114. Erickson, P, J. Gao, K. S. Chang, T. Look, E. Whisenant, S. Raimondi, R. Lasher, J. Trujillo, J. Rowley, & H. Drabkin: Identification of breakpoints in t(8, 21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80, 1825-1831 (1992).
115. Miyoshi, H, T. Kozu, K. Shimizu, K. Enomoto, N. Maseki, Y. Kaneko, N. Kamada, & M. Ohki: The t(8, 21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 12, 2715-2721 (1993). (Pubitemid 23218321)
116. Tighe, J E & F. Calabi: Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8, 21) of acute myeloid leukemia M2. Blood 84, 2115-2121 (1994). (Pubitemid 24296366)
117. Tighe, J E & F. Calabi: t(8, 21) breakpoints are clustered between alternatively spliced exons of MTG8. Clin Sci (Lond) 89, 215-218 (1995).
118. Zhang, Y, P. Strissel, R. Strick, J. Chen, G. Nucifora, M. M. Le Beau, R. A. Larson, & J. D. Rowley: Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8, 21) leukemia. Proc Natl Acad Sci USA 99, 3070-3075 (2002). (Pubitemid 34240587)
119. Peterson, L F, A. Boyapati, E. Y. Ahn, J. R. Biggs, O. A. Joo, M. C. Lo, M. Yan, & D. E. Zhang: Acute myeloid leukemia with the 8q22, 21q22 translocation: secondary mutational events and alternative t(8, 21) transcripts. Blood 110: 799-805 (2007). (Pubitemid 47267414)
120. Calabi, F, R. Pannell, & G. Pavloska: Gene targeting reveals a crucial role for MTG8 in the gut. Mol Cell Biol 21, 5658-5666 (2001). (Pubitemid 32702468)
121. Sacchi, N, F. Tamanini, R. Willemsen, S. Denis- Donini, S. Campiglio, & A. T. Hoogeveen: Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells. Oncogene 16, 2609-2615 (1998). (Pubitemid 28264038)
122. Alishahi, A, N. Koyano-Nakagawa, & Y. Nakagawa: Regional Expression of MTG Genes in the Developing Mouse Central Nervous System. Developmental Dynamics 238, 2095-2102 (2009).
123. Wolford, J K & M. Prochazka: Structure and expression of the human MTG8/ETO gene. Gene 212, 103- 109 (1998). (Pubitemid 28269138)
124. Erickson, P F, M. Robinson, G. Owens, & H. A. Drabkin: The Eto Portion of Acute Myeloid-Leukemia T(8- 21) Fusion Transcript Encodes A Highly Evolutionarily Conserved, Putative Transcription Factor. Cancer Research 54, 1782-1786 (1994). (Pubitemid 24116186)
125. Okumura, A J, L. F. Peterson, F. Okumura, A. Boyapati, & D. E. Zhang: t(8, 21)(q22, q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNAbinding sequences to differentially regulate gene expression. Blood 112, 1392-1401 (2008).
126. Feinstein, P G, K. Kornfeld, D. S. Hogness, & R. S. Mann: Identification of homeotic target genes in Drosophila melanogaster including nervy, a protooncogene homologue. Genetics 140, 573-586 (1995).
127. Terman, J R & A. L. Kolodkin: Nervy links protein kinase a to plexin-mediated semaphorin repulsion. Science 303, 1204-1207 (2004). (Pubitemid 38233588)
128. Fukuyama, T, E. Sueoka, Y. Sugio, T. Otsuka, Y. Niho, K. Akagi, & T. Kozu: MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMPdependent protein kinase in lymphocytes. Oncogene 20, 6225-6232 (2001). (Pubitemid 32964435)
129. Corpora, T, L. Roudaia, Z. M. Oo, W. Chen, E. Manuylova, X. W. Cai, M. J.
130. Liu, Y, W. Chen, J. Gaudet, M. D. Cheney, L. Roudaia, T. Cierpicki, R. C. Klet, K. Hartman, T. M. Laue, N. A. Speck, & J. H. Bushweller: Structural Basis for Recognition of SMRT/N-CoR by the MYND Domain and Its Contribution to AML1/ETO's Activity. Cancer Cell 11, 483-497 (2007). (Pubitemid 46856906)
131. Zhang, J, M. Kalkum, S. Yamamura, B. T. Chait, & R. G. Roeder: E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305, 1286-1289 (2004). (Pubitemid 39129232)
132. Kitabayashi, I, K. Ida, F. Morohoshi, A. Yokoyama, N. Mitsuhashi, K. Shimizu, N. Nomura, Y. Hayashi, & M. Ohki: The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol 18, 846-858 (1998). (Pubitemid 28063418)
133. Zhang, J, B. A. Hug, E. Y. Huang, C. W. Chen, V. Gelmetti, M. Maccarana, S. Minucci, P. G. Pelicci, & M. A. Lazar: Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol 21, 156-163 (2001).
134. Liu, Y, M. D. Cheney, J. J. Gaudet, M. Chruszcz, S. M. Lukasik, D. Sugiyama, J. Lary, J. Cole, Z. Dauter, W. Minor, N. A. Speck, & J. H. Bushweller: The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 9, 249-260 (2006).
135. Lutterbach, B, J. J. Westendorf, B. Linggi, A. Patten, M. Moniwa, J. R. Davie, K. D. Huynh, V. J. Bardwell, R. M. Lavinsky, M. G. Rosenfeld, C. Glass, E. Seto, & S. W. Hiebert: ETO, a target of t(8, 21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18, 7176-7184 (1998). (Pubitemid 28533037)
136. Wang, J, T. Hoshino, R. L. Redner, S. Kajigaya, & J. M. Liu: ETO, fusion partner in t(8, 21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95, 10860-10865 (1998). (Pubitemid 28413159)
137. Ahn, E Y, M. Yan, O. A. Malakhova, M. C. Lo, A. Boyapati, H. B. Ommen, R. Hines, P. Hokland, & D. E. Zhang: Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci USA 105, 17103- 17108 (2008).
138. van de Locht, L T, T. F. Smetsers, S. Wittebol, R. A. Raymakers, & E. J. Mensink: Molecular diversity in AML1/ETO fusion transcripts in patients with t(8, 21) positive acute myeloid leukaemia. Leukemia 8, 1780-1784 (1994). (Pubitemid 24323799)
139. Buchholz, F, Y. Refaeli, A. Trumpp, & J. M. Bishop: Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Reports 1, 133-139 (2000).
140. Higuchi, M, D. O'Brien, P. Kumaravelu, N. Lenny, E. J. Yeoh, & J. R. Downing: Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8, 21) acute myeloid leukemia. Cancer Cell 1, 63-74 (2002). (Pubitemid 41039177)
141. Yan, M, S. A. Burel, L. F. Peterson, E. Kanbe, H. Iwasaki, A. Boyapati, R. Hines, K. Akashi, & D. E. Zhang: Deletion of an AML1-ETO C-terminal NcoR/SMRTinteracting region strongly induces leukemia development. Proc Natl Acad Sci USA 101, 17186-17191 (2004). (Pubitemid 39627795)
142. Yan, M, E. Kanbe, L. F. Peterson, A. Boyapati, Y. Miao, Y. Wang, I. M. Chen, Z. Chen, J. D. Rowley, C. L. Willman, & D. E. Zhang: A previously unidentified alternatively spliced isoform of t(8, 21) transcript promotes leukemogenesis. Nat Med 12, 945-949 (2006). (Pubitemid 44175147)
143. Hackanson, B, M. Abdelkarim, J. H. Jansen, & M. Lubbert: NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells. Leukemia 24, 860-861 (2010).
144. Kramer, O H, S. Muller, M. Buchwald, S. Reichardt, & T. Heinzel: Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J 22, 1369-1379 (2008). (Pubitemid 351656778)
145. Lu, Y, Z. G. Peng, T. T. Yuan, Q. Q. Yin, L. Xia, & G. Q. Chen: Multi-sites cleavage of leukemogenic AML1- ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Leukemia 22, 378-386 (2008). (Pubitemid 351250543)
146. Osman, D, V. Gobert, F. Ponthan, O. Heidenreich, M. Haenlin, & L. Waltzer: A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO. Proc Natl Acad Sci USA 106, 12043- 12048 (2009).
147. Yeh, J R J, K. M. Munson, Y. L. Chao, Q. P. Peterson, C. A. Macrae, & R. T. Peterson: AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 135, 401-410 (2008). (Pubitemid 351228431)
148. Yeh, J R J, K. M. Munson, K. E. Elagib, A. N. Goldfarb, D. A. Sweetser, & R. T. Peterson: Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nature Chemical Biology 5, 236-243 (2009).
149. Yergeau, D A, C. J. Hetherington, Q. Wang, P. Zhang, A. H. Sharpe, M. Binder, M. Marin-Padilla, D. G. Tenen, N. A. Speck, & D. E. Zhang: Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15, 303-306 (1997). (Pubitemid 27098728)
150. Okuda, T, Z. Cai, S. Yang, N. Lenny, C. Lyu, van Deursen JMA, H. Harada, & J. R. Downing: Expression of a knocked-In AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91, 3134-3143 (1998). (Pubitemid 28193861)
151. Oravecz-Wilson, K I, S. T. Philips, O. H. Yilmaz, H. M. Ames, L. Li, B. D. Crawford, A. M. Gauvin, P. C. Lucas, K. Sitwala, J. R. Downing, S. J. Morrison, & T. S. Ross: Persistence of Leukemia-Initiating Cells in a Conditional Knockin Model of an Imatinib-Responsive Myeloproliferative Disorder. Cancer Cell 16, 137-148 (2009).
152. Fenske, T S, G. Pengue, V. Mathews, P. T. Hanson, S. E. Hamm, N. Riaz, & T. A. Graubert: Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci USA 101, 15184-15189 (2004). (Pubitemid 39391739)
153. de Guzman, C G, A. J. Warren, Z. Zhang, L. Gartland, P. Erickson, H. Drabkin, S. W. Hiebert, & C. A. Klug: Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22, 5506-5517 (2002). (Pubitemid 34755760)
154. Schwieger, M, J. Lohler, J. Friel, M. Scheller, I. Horak, & C. Stocking: AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 196, 1227-1240 (2002). (Pubitemid 35304188)
155. Grisolano, J L, J. O'Neal, J. Cain, & M. H. Tomasson: An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 100, 9506- 9511 (2003). (Pubitemid 37033958)
156. Schessl, C, V. P. Rawat, M. Cusan, A. Deshpande, T. M. Kohl, P. M. Rosten, K. Spiekermann, R. K. Humphries, S. Schnittger, W. Kern, W. Hiddemann, L. Quintanilla- Martinez, S. K. Bohlander, M. Feuring-Buske, & C. Buske: The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115, 2159-2168 (2005). (Pubitemid 41134157)
157. Mulloy, J C, J. Cammenga, F. J. Berguido, K. Wu, P. Zhou, R. L. Comenzo, S. Jhanwar, M. A. Moore, & S. D. Nimer: Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 102, 4369-4376 (2003). (Pubitemid 37494097)
158. Basecke, J, M. Schwieger, F. Griesinger, B. Schiedlmeier, G. Wulf, L. Trumper, & C. Stocking: AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. Leuk Lymphoma 46, 265-272 (2005). (Pubitemid 40185958)
159. Linggi, B, C. Muller-Tidow, L. L. van de, M. Hu, J. Nip, H. Serve, W. E. Berdel, R. B. van der, D. E. Quelle, J. D. Rowley, J. Cleveland, J. H. Jansen, P. P. Pandolfi, & S. W. Hiebert: The t(8, 21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8, 743-750 (2002). (Pubitemid 34778729)
160. Mulloy, J C, V. Jankovic, M. Wunderlich, R. Delwel, J. Cammenga, O. Krejci, H. Zhao, P. J. Valk, B. Lowenberg, & S. D. Nimer: AML1-ETO fusion protein upregulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci USA 102, 4016-4021 (2005). (Pubitemid 40392508)
161. Peterson, L F, M. Yan, & D. E. Zhang: The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8, 21) fusion protein AML1-ETO. Blood 109, 4392-4398 (2007). (Pubitemid 46743408)
162. Alcalay, M, N. Meani, V. Gelmetti, A. Fantozzi, M. Fagioli, A. Orleth, D. Riganelli, C. Sebastiani, E. Cappelli, C. Casciari, M. T. Sciurpi, A. R. Mariano, S. P. Minardi, L. Luzi, H. Muller, P. P. Di Fiore, G. Frosina, & P. G. Pelicci: Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112, 1751-1761 (2003). (Pubitemid 38063733)
163. Valk, P J, R. G. Verhaak, M. A. Beijen, C. A. Erpelinck, Barjesteh van Waalwijk van Doorn-Khosrovani S., J. M. Boer, H. B. Beverloo, M. J. Moorhouse, P. J. van der Spek, B. Lowenberg, & R. Delwel: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350, 1617-1628 (2004). (Pubitemid 38528701)
164. Ross, M E, R. Mahfouz, M. Onciu, H. C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, R. C. Ribeiro, J. E. Rubnitz, K. Girtman, W. K. Williams, S. C. Raimondi, D. C. Liang, L. Y. Shih, C. H. Pui, & J. R. Downing: Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104, 3679-3687 (2004). (Pubitemid 39564445)
165. Li, Z, J. Lu, M. Sun, S. Mi, H. Zhang, R. T. Luo, P. Chen, Y. Wang, M. Yan, Z. Qian, M. B. Neilly, J. Jin, Y. Zhang, S. K. Bohlander, D. E. Zhang, R. A. Larson, M. M. Le Beau, M. J. Thirman, T. R. Golub, J. D. Rowley, & J. Chen: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 105, 15535-15540 (2008).
166. Fazi, F, S. Racanicchi, G. Zardo, L. M. Stames, M. Mancini, L. Travaglini, D. Diverio, E. Ammatuna, G. Cimino, F. Lo-Coco, F. Grignani, & C. Nervi: Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12, 457-466 (2007). (Pubitemid 350046404)
167. Gardini, A, M. Cesaroni, L. Luzi, A. J. Okumura, J. R. Biggs, S. P. Minardi, E. Venturini, D. E. Zhang, P. G. Pelicci, & M. Alcalay: AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet 4, e1000275 (2008).
168. Heinzel, T, R. M. Lavinsky, T. M. Mullen, M. Soderstrom, C. D. Laherty, J. Torchia, W. M. Yang, G. Brard, S. D. Ngo, J. R. Davie, E. Seto, R. N. Eisenman, D. W. Rose, C. K. Glass, & M. G. Rosenfeld: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387, 43-48 (1997). (Pubitemid 27202643)
169. Amann, J M, J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N. Lenny, J. R. Downing, S. Meyers, & S. W. Hiebert: ETO, a target of t(8, 21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21, 6470-6483 (2001). (Pubitemid 32927415)
170. Gottlicher, M, S. Minucci, P. Zhu, O. H. Kramer, A. Schimpf, S. Giavara, J. P. Sleeman, C. F. Lo, C. Nervi, P. G. Pelicci, & T. Heinzel: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20, 6969-6978 (2001). (Pubitemid 34062289)
171. Liu, S, R. B. Klisovic, T. Vukosavljevic, J. Yu, P. Paschka, L. Huynh, J. Pang, P. Neviani, Z. Liu, W. Blum, K. K. Chan, D. Perrotti, & G. Marcucci: Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETOpositive acute myeloid leukemia cells. J Pharmacol Exp Ther 321, 953-960 (2007). (Pubitemid 46762689)
172. Yang, G, M. A. Thompson, S. J. Brandt, & S. W. Hiebert: Histone deacetylase inhibitors induce the degradation of the t(8, 21) fusion oncoprotein. Oncogene 26, 91-101 (2007). (Pubitemid 46067334)
173. Klisovic, M I, E. A. Maghraby, M. R. Parthun, M. Guimond, A. R. Sklenar, S. P. Whitman, K. K. Chan, T. Murphy, J. Anon, K. J. Archer, L. J. Rush, C. Plass, M. R. Grever, J. C. Byrd, & G. Marcucci: Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350-358 (2003). (Pubitemid 36266913)
174. Liu, S, T. Shen, L. Huynh, M. I. Klisovic, L. J. Rush, J. L. Ford, J. Yu, B. Becknell, Y. Li, C. Liu, T. Vukosavljevic, S. P. Whitman, K. S. Chang, J. C. Byrd, D. Perrotti, C. Plass, & G. Marcucci: Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65, 1277-1284 (2005). (Pubitemid 40270154)
175. Lasa, A, M. J. Carnicer, A. Aventin, C. Estivill, S. Brunet, J. Sierra, & J. Nomdedeu: MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia 18, 1231- 1237 (2004). (Pubitemid 39023133)
176. Berg, T, Y. Guo, M. Abdelkarim, M. Fliegauf, & M. Lubbert: Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leukemia Research 31, 497-506 (2007). (Pubitemid 46206089)
177. Figueroa, M E, S. Lugthart, Y. S. Li, C. Erpelinck- Verschueren, X. T. Deng, P. J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, F. Campagne, M. Mazumdar, J. M. Greally, P. J. M. Valk, B. Lowenberg, R. Delwel, & A. Melnick: DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. Cancer Cell 17, 13-27 (2010).
178. Wilson, N K, S. D. Foster, X. N. Wang, K. Knezevic, J. Schutte, P. Kainnakis, P. M. Chilarska, S. Kinston, W. H. Ouwehand, E. Dzierzak, J. E. Pimanda, M. F. T. R. de Bruijn, & B. Gottgens: Combinatorial Transcriptional Control In Blood Stem/Progenitor Cells: Genome-wide Analysis of Ten Major Transcriptional Regulators. Cell Stem Cell 7, 532-544 (2010).
179. Wildonger, J & R. S. Mann: The t(8, 21) translocation converts AML1 into a constitutive transcriptional repressor. Development 132, 2263-2272 (2005). (Pubitemid 40872797)
180. Sinenko, S A, T. Hung, T. Moroz, Q. M. Tran, S. Sidhu, M. D. Cheney, N. A. Speck, & U. Banerjee: Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model. Blood 116, 4612-4620 (2010).
181. Nishida, S, N. Hosen, T. Shirakata, K. Kanato, M. Yanagihara, S. Nakatsuka, Y. Hoshida, T. Nakazawa, Y. Harada, N. Tatsumi, A. Tsuboi, M. Kawakami, Y. Oka, Y. Oji, K. Aozasa, I. Kawase, & H. Sugiyama: AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107, 3303-3312 (2006).